curasan AG Scouts for Sales Partners for ATRŪ

Saturday, 31 July 2010

curasan AG, listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8), has commenced with the pre-marketing activities for the launch of its new product ATR® (Advanced Tissue Regeneration). ATR® is a standardised system for extracting growth factors, which support wound healing and tissue regeneration. The areas of application include severe skin damage such as ulcers, large-area burns, skin transplantations, cartilage and cell culture or chronic wounds. Furthermore, the product can have a favourable impact on the wound healing process for the optimised regeneration of bones and mucous membranes in plastic surgery, in oral and maxillofacial surgery and implantology. “ATR® is an attractive proposition for various specialised enterprises on account of its wide range of applications. Since a marketable product is now available, we can actively pursue negotiations with potential sales partners with immediate effect,” explains Hans Dieter Rössler, CEO of curasan AG. Initially, the activities are aimed at Germany and the European market. However, in the medium term curasan AG anticipates enormous potential for ATR®, above all, in the US market. With the help of ATR®, autologous platelet-mediator-concentrate (PMC) is extracted from the patient’s own blood, which ensures a high degree of compatibility. PMC supplies the important growth factors for wound healing and tissue regeneration, which can then be brought directly in the wound area. ATR® is a single use device that requires neither machines nor external laboratories; hence, there are no investment costs and no costs incurred in the services provided by third parties. The ATR® system contains everything that is needed to extract the concentrate either in the doctor’s practice or in the operating room. Background information about curasan AG: Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.